Why the study?
The study aimed to determine the burden of thromboembolic events in patients with solid tumors and identify the risk factors related to their development.
This study highlights the high burden of venous thromboembolism, particularly DVT and PE, in patients with solid tumors, often associated with metastatic disease and anti-neoplastic therapy.
Answers are grounded in this paper and cite their sources.
High VTE burden in solid tumors warrants clinical vigilance; leaves open optimal prophylaxis strategies pending prospective trials.
INTRODUCTION: The relationship between cancers and thromboembolic events is well established. In our study, we aim to determine the burden of thromboembolic events in patients with solid tumors and identify the risk factors related to their development. MATERIALS & METHODS: Data on patients with solid tumors and thromboembolism between January 2013 and September 2014 were collected and analyzed. RESULTS: During the study period 174 patients were identified. Of which, 172 (98.9%) had venous thrombus embolism, 137 (79%) were diagnosed with deep vein thromboses, 67 (38.5%) with pulmonary embolism, 84 (48.3%) were symptomatic and 90 (51.7) were incidental at diagnosis. The most common patients and disease characteristics were female sex, high body mass index (BMI), metastatic stage, colorectal and breast primaries, and anti-neoplastic therapy. CONCLUSION: Our study confirmed the high burden of thromboembolic events in cancer patients and the relevant factors associated with its development.
No takes yet. Share an insight, caveat, or question.
Bazarbashi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: